RECRUITING

Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with radiation therapy called stereotactic radiosurgery (SRS).

Official Title

Development of a Clinical CEST MR Fingerprinting Method for Treatment Response Assessment in Brain Metastases

Quick Facts

Study Start:2022-09-22
Study Completion:2027-09-22
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05559853

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age ≥ 18 years
  2. * Able to understand and give informed consent
  3. * No known cancer diagnosis
  4. * Age ≥ 18 years
  5. * Able to understand and give informed consent
  6. * At least one untreated brain metastasis \> 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist)
  7. * Age ≥ 18 years
  8. * Able to understand and give informed consent
  9. * At least one untreated brain metastasis \> 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist)
  10. * Planned SRS treatment
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Ouri Cohen, PhD
CONTACT
646-608-8259
coheno1@mskcc.org
Nelson Moss, MD
CONTACT
212-639-7075
mossn@mskcc.org

Principal Investigator

Ouri Cohen, PhD
PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center

Study Locations (Sites)

Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065
United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

  • Ouri Cohen, PhD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-09-22
Study Completion Date2027-09-22

Study Record Updates

Study Start Date2022-09-22
Study Completion Date2027-09-22

Terms related to this study

Keywords Provided by Researchers

  • Brain Metastases
  • Healthy Volunteers
  • metastatic brain tumor
  • metastatic brain cancer
  • Brain Metastases, Adult
  • MRI
  • untreated brain metastasis
  • CEST-MRF
  • chemical exchange saturation transfer magnetic resonance fingerprinting
  • 22-191
  • Memorial Sloan Kettering Cancer Center

Additional Relevant MeSH Terms

  • Brain Metastases
  • Brain Metastases, Adult
  • Metastatic Brain Tumor
  • Metastatic Brain Cancer